Enhanced replication and immunogenicity of a genome-modified non-replicating vaccinia virus Tiantan strain for robust low-dose protection in mice
Journal of Virology · 18.08.2026 · 100 (8)
DOI: 10.1128/jvi.00943-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.08.2026. Verfasst von Jiao Ren und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, Na…. Hauptthemen laut MEDLINE: Vaccinia virus, Virus Replication, Vaccinia, Immunogenicity, Vaccine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Major Science and Technology Projects of China, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
A non-replicating Tiantan strain-based vaccinia virus (NTV) holds significant application prospects for vaccination and gene therapy and has recently entered clinical trials as a novel and safer vaccine candidate against monkeypox. However, optimization is still required, particularly regarding its production capacity and immunogenicity. In this study, a recombinant virus was constructed by modifying the F1L and C7L genes in a non-replicating viral backbone using CRISPR/Cas9-mediated gene editing and homologous recombination. The resulting construct, designated NTV-ΔF1L-C7L, exhibited significantly enhanced replication in vaccine production cell lines, with viral yields increasing by more than 680-fold in MRC-5 cells compared to those of the parental NTV. Its pathogenicity in mice was significantly reduced, showing more than a 10-fold decrease compared to the pathogenicity of the vaccinia virus Tiantan strain (VTT). Following two intramuscular doses, NTV-ΔF1L-C7L elicited high titers of orthopoxvirus-specific IgG and neutralizing antibodies against vaccinia and monkeypox viruses, along with a robust cellular immune response exhibiting a Th1 bias, which was significantly stronger than that induced by either parental NTV or VTT vaccination. Complete protection (100%) against a lethal challenge with the vaccinia virus Western Reserve strain was achieved in mice immunized with either a low dose (10 3 PFU) or a single dose (10⁵ PFU) of NTV-ΔF1L-C7L, comparable to that conferred by VTT. These findings demonstrate that NTV-ΔF1L-C7L combines high safety with enhanced replication and immunogenicity, supporting its value as a novel vaccine vector and its potential application in controlling the current global monkeypox outbreak. IMPORTANCE A highly attenuated NTV exhibits an improved safety profile; however, its production capacity and immunogenicity require optimization for clinical application. In this study, a novel recombinant virus, NTV-ΔF1L-C7L, was developed by targeting the deletion of F1L and the insertion of C7L into the NTV backbone. This attenuated live vaccine, NTV-ΔF1L-C7L, demonstrates several significant advantages. Its robust in vitro replication supports scalability for large-scale vaccine production. It has demonstrated strong immunoprotective efficacy in mice while maintaining a high safety margin, exhibiting reduced pathogenicity in vivo , and inducing robust humoral and cellular immune responses against vaccinia and monkeypox virus. These immune responses confer complete protection against lethal VACV challenge at low-dose or single-dose immunization. These findings establish a solid experimental foundation for the further development of NTV-ΔF1L-C7L as a next-generation VACV-based vector or a candidate vaccine against mpox.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC,…
ORCID-Profile: Jiao Ren, Shiyuan Liu, Houwen Tian, Wenjie Tan
Förderung
- National Major Science and Technology Projects of China
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Ren, J., Liu, S., Yuan, H., Wu, Y., Zhao, Z., Wang, Y., Huang, B., Wang, W., Tian, H., & Tan, W. (2026). Enhanced replication and immunogenicity of a genome-modified non-replicating vaccinia virus Tiantan strain for robust low-dose protection in mice. Journal of Virology, 100(8). https://doi.org/10.1128/jvi.00943-26
Vancouver
Ren J, Liu S, Yuan H, Wu Y, Zhao Z, Wang Y, et al. Enhanced replication and immunogenicity of a genome-modified non-replicating vaccinia virus Tiantan strain for robust low-dose protection in mice. Journal of Virology. 2026;100(8). doi:10.1128/jvi.00943-26
BibTeX
@article{Ren2026,
author = {Ren, Jiao and Liu, Shiyuan and Yuan, Hang and Wu, Yiyi and Zhao, Zhihao and Wang, Yawei and Huang, Baoying and Wang, Wenling and Tian, Houwen and Tan, Wenjie},
title = {Enhanced replication and immunogenicity of a genome-modified non-replicating vaccinia virus Tiantan strain for robust low-dose protection in mice},
journal = {Journal of Virology},
year = {2026},
volume = {100},
number = {8},
doi = {10.1128/jvi.00943-26}
}
EUVIMED